• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

Histogenics

Histogenics completes transformation into Ocugen with $7m deal for NeoCart

May 13, 2019 By Brad Perriello

UPDATED May 14, 2019, with comment from Medavate. Histogenics (NSDQ:HSGX) said today that it completed another step on its transformation into clinical-stage biopharmaceutical company Ocugen, with a nearly $7 million deal to sell its NeoCart regenerative knee treatment to Medavate. The $6.5 million all-cash deal, signed May 8, will see all of the NeoCart assets pass […]

Filed Under: Featured, Mergers & Acquisitions, Orthopedics, Regenerative Medicine, Wall Street Beat Tagged With: Histogenics, Medavate, ocugen

Histogenics to merge with Ocugen

April 9, 2019 By Fink Densford

Histogenics (NSDQ:HSGX) said yesterday that it inked a definitive merger agreement with Ocugen through which both companies will combine into a single publicly-traded, clinical-stage biopharmaceutical company. The combined entity will operate under the Ocugen name, the companies said. As part of the deal, Ocugen’s shareholders will become the majority owners of Histogenics outstanding common stock upon […]

Filed Under: Business/Financial News, Featured, Mergers & Acquisitions, Wall Street Beat Tagged With: Histogenics, ocugen

Histogenics to lay off all but 1 employee in restructuring

March 18, 2019 By Sarah Faulkner

Histogenics (NSDQ:HSGX) said last week that its board of directors approved a restructuring plan that would result in layoffs for all but one of the company’s employees. The layoffs include CEO Adam Gridley and COO Stephen Kennedy. Gridley and Kennedy plan to evaluate “strategic alternatives” for the company in consulting capacities alongside up to four other […]

Filed Under: Business/Financial News, Featured, Wall Street Beat Tagged With: Histogenics

Histogenics to lay off 65% of workforce, including CMO & CBO, in restructuring

January 24, 2019 By Fink Densford

Histogenics (NSDQ:HSGX) said today that its board of directors approved a restructuring plan with a 65% reduction in its workforce, including the the company’s chief medical officer Dr. Lynne Kelley and chief business officer Donald Haut, according to an SEC filing. The move comes after the Waltham, Mass.-based company decided to discontinue development of its NeoCart product […]

Filed Under: Business/Financial News, Featured, Wall Street Beat Tagged With: Histogenics

Histogenics plunges on missed endpoint in NeoCart trial

September 5, 2018 By Brad Perriello

UPDATE: Now includes comment from CEO Adam Gridley Histogenics (NSDQ:HSGX) said today that a pivotal trial of its regenerative NeoCart knee treatment failed to meet its primary endpoint, sending its share price down some -70%. Waltham, Mass.-based Histogenics said NeoCart, which is designed to repair knee cartilage damage using cells harvested from the surface of patients’ […]

Filed Under: Clinical Trials, Orthopedics, Regenerative Medicine, Wall Street Beat Tagged With: Histogenics

Histogenics inks $10 stock sale deal, beats the Street with Q4, 2017 earnings

March 15, 2018 By Fink Densford

Histogenics (NSDQ:HSGX) today announced a $10 million sale deal and released its fourth quarter and full year 2017 earnings, seeing shares fall as losses grew, despite the company beating The Street with its loss-per-share numbers. The company said it inked an equity distribution agreement with Cannacord Genuity to sell up to $10 million, with Cannacord acting as […]

Filed Under: Business/Financial News, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Histogenics

Histogenics inks deal to develop Neocart for the Japanese market

December 22, 2017 By Sarah Faulkner

Histogenics (NSDQ:HSGX) has inked a deal with Medinet to develop and commercialize its Neocart implant for the Japanese market. The Waltham, Mass.-based company’s Neocart implant is designed to repair knee cartilage damage. The product is made using a patient’s own cells, harvested from the surface of the patient’s femur. Get the full story at our sister site, Drug […]

Filed Under: Implants, Orthopedics, Pain Management, Regenerative Medicine Tagged With: Histogenics, medinet

Relievant Medsystems taps ex-Cameron Health chief Hykes for CEO | Personnel Moves, Sept. 26, 2017

September 26, 2017 By Brad Perriello

Relievant Medsystems said it named former Cameron Medical chief Kevin Hykes to be its new CEO, effective immediately. Hykes, who led Cameron Health to a $1.35 billion buyout in 2012 by Boston Scientific (NYSE:BSX), replaced Alex DiNello, who was named COO, Relievant said. Relievant makes the Intracept device for treating lower back pain. Hykes was most recently […]

Filed Under: Wall Street Beat Tagged With: Breathtec Biomedical Inc, Histogenics, HistoSonics Inc., integer, lombardmedical, Masimo, Medizone, pulmodyne, Relievant Medsystems Inc., RTI Surgical

Histogenics finishes trial planning in pursuit of Japanese NeoCart approval

May 8, 2017 By Fink Densford

Histogenics (NSDQ:HSGX) said today it completed all formal consultations with the Japanese Pharmaceuticals and Medical Devices Agency’s Office of Cellular and Tissue-based Products as it seeks regulatory clearance for its NeoCart in Japan. NeoCart is designed to stimulate the body’s ability to regenerate cartilage in the knee, using neocartilagenous tissue developed from patients’ chondrocyte cells, the Waltham, […]

Filed Under: Regenerative Medicine, Regulatory/Compliance Tagged With: Histogenics

Histogenics raises $30m for NeoCart regenerative knee treatment

October 13, 2016 By Brad Perriello

Histogenics (NSDQ:HSGX) said last month that it raised $30 million in a private placement it plans to use for a pivotal trial of its NeoCart regenerative knee treatment. The Waltham, Mass.-based company said the round, of equity, convertible stock and warrants, was led by new institutional investors and some of its existing backers. The cash […]

Filed Under: Funding Roundup, Orthopedics, Regenerative Medicine Tagged With: Histogenics

Histogenics inks supply deal with Collagen Solutions

September 18, 2015 By Fink Densford

Regenerative medicine-focused Histogenics said Wednesday it signed a supply deal with U.K.-based Collagen Solutions. Collagen Solutions will provide collagen material sources for use in Histogenics investigational NeoCart which is being designed to repair knee cartilage damage.  The NeoCart product is currently in phase 3 trials. “Collagen Solutions has again demonstrated that it can provide materials […]

Filed Under: Regenerative Medicine Tagged With: Histogenics

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS